Rising Use Of E-Cigarettes
BMI View : There is a growing demand for smoking cessation products as global tobacco consumption remains stubbornly highly despite the increase in global health warning labels on tobacco packages and national anti-tobacco mass-media campaigns. Factors driving this include ongoing marketing efforts by the tobacco industry and population growth in countries with high tobacco consumption. With tobacco consumption linked to negative healthcare outcomes, governments are looking to diversify the provision of treatment for smokers looking to quit.
In February 2014, GlaxoSmithKline (GSK) and Johnson & Johnson (J&J) called for more stringent regulation of e-cigarettes. According to e-mails from a GSK executive that were made public in mid-February 2014, the company stated that Europe should follow the lead of the UK, which was looking to enforce requirements for e-cigarettes to be licensed as medicines much the way other nicotine-replacement therapy products are. J&J, also stated that it is 'strongly in favour of' regulating all non-tobacco nicotine products, including e-cigarettes, as medicines.
In March 2014, the European Parliament and Council announced that it was revising the Tobacco Product Directive (TPD). Under this directive, advertising of nicotine-containing devices that are not licensed as medicines will be prohibited, products will be required to carry health warnings, meet purity and emissions standards that are yet to be defined, provide data on nicotine uptake, be subject to restrictions on total nicotine content, and suppliers will be required to bear full responsibility for quality and safety when used 'under normal or reasonably foreseeable conditions'. Dates for enactment are yet to be specified, but legislation is expected to be required in member states by 2016, and full compliance by 2017. In practice, this means that from 2017 at the latest, suppliers will have to choose between the probably lower manufacturing costs but greater marketing restrictions imposed by the TPD, or to accept the higher manufacturing costs but other benefits of medicines licensing.
|UK NHS: Prescription Of Nicotine Cessation Products (Thousands)|